Analyst Price Targets — FTRE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 12:25 pm | — | Deutsche Bank | $20.00 | $19.93 | TheFly | Fortrea price target raised to $20 from $18 at Deutsche Bank |
| July 30, 2026 11:51 am | Eric Coldwell | Robert W. Baird | $23.00 | $20.40 | TheFly | Fortrea price target raised to $23 from $21 at Baird |
| July 30, 2026 9:09 am | — | Barclays | $22.00 | $20.40 | TheFly | Fortrea price target raised to $22 from $18 at Barclays |
| July 13, 2026 11:43 am | — | Mizuho Securities | $16.00 | $17.76 | TheFly | Fortrea price target raised to $16 from $13 at Mizuho |
| June 24, 2026 8:50 am | Luke Sergott | Barclays | $18.00 | $16.46 | TheFly | Fortrea price target raised to $18 from $16 at Barclays |
| May 7, 2026 12:41 pm | Justin Bowers | Deutsche Bank | $14.00 | $16.14 | TheFly | Fortrea price target raised to $14 from $11 at Deutsche Bank |
| May 6, 2026 1:29 pm | — | Truist Financial | $19.00 | $15.16 | TheFly | Fortrea price target raised to $19 from $16 at Truist |
| May 6, 2026 10:45 am | — | Robert W. Baird | $20.00 | $14.53 | TheFly | Fortrea price target raised to $20 from $15 at Baird |
| May 6, 2026 9:37 am | — | Barclays | $16.00 | $14.53 | TheFly | Fortrea price target raised to $16 from $11 at Barclays |
| April 14, 2026 10:42 am | — | Barclays | $11.00 | $9.38 | TheFly | Fortrea price target lowered to $11 from $12 at Barclays |
Latest News for FTRE
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic…
Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.
Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FTRE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.